

# Iria Grande

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2460094/publications.pdf>

Version: 2024-02-01

78  
papers

4,247  
citations

201674

27  
h-index

114465

63  
g-index

83  
all docs

83  
docs citations

83  
times ranked

4984  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluating the Effect of a Telepsychiatry Educational Program on the Awareness, Knowledge, Attitude, and Skills of Telepsychiatry Among Spanish Psychiatrists during COVID-19 Pandemic. <i>Telemedicine Journal and E-Health</i> , 2023, 29, 102-108.	2.8	3
2	Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study. <i>Journal of Psychopharmacology</i> , 2022, 36, 566-577.	4.0	12
3	Trajectories of suicidal ideation after first episode psychosis: a growth mixture modeling approach. <i>Acta Psychiatrica Scandinavica</i> , 2021, 143, 418-433.	4.5	17
4	Study Protocol "Coping With the Pandemics: What Works Best to Reduce Anxiety and Depressive Symptoms. <i>Frontiers in Psychiatry</i> , 2021, 12, 642763.	2.6	3
5	Consensus on nomenclature for clinical staging models in bipolar disorder: A narrative review from the International Society for Bipolar Disorders (ISBD) Staging Task Force. <i>Bipolar Disorders</i> , 2021, 23, 659-678.	1.9	27
6	La humanización en los planes de salud mental en España. <i>Revista De Psiquiatría Y Salud Mental</i> , 2021, , .	1.8	2
7	Physical health in affective disorders: a narrative review of the literature. <i>Revista Brasileira De Psiquiatria</i> , 2021, 43, 621-630.	1.7	12
8	Exploring Risk and Resilient Profiles for Functional Impairment and Baseline Predictors in a 2-Year Follow-Up First-Episode Psychosis Cohort Using Latent Class Growth Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 73.	2.4	14
9	P.0073 The RECONNECT study: effectiveness of vortioxetine (10-20 mg/day) in patients with major depressive disorder comorbid with generalised anxiety disorder. <i>European Neuropsychopharmacology</i> , 2021, 53, S52-S53.	0.7	1
10	Personalized treatment in bipolar disorder. , 2020, , 423-436.		1
11	P.831 Trajectories of suicidal ideation after a first-episode psychosis: a growth mixture modeling approach. <i>European Neuropsychopharmacology</i> , 2020, 40, S462-S463.	0.7	0
12	The Suicide Prevention and Intervention Study (SURVIVE): Study protocol for a multisite cohort study with nested randomized-controlled trials. <i>Revista De Psiquiatría Y Salud Mental</i> , 2020, , .	1.8	1
13	Risk Calculators in Bipolar Disorder: A Systematic Review. <i>Brain Sciences</i> , 2020, 10, 525.	2.3	18
14	The interplay between acute bacterial skin and skin structure infections and depression. <i>Current Opinion in Infectious Diseases</i> , 2020, 33, 1.	3.1	3
15	Predictors of Bipolar Disorder Versus Schizophrenia Diagnosis in a Multicenter First Psychotic Episode Cohort. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	17
16	Lifetime Psychotic Symptoms, Subthreshold Depression and Cognitive Impairment as Barriers to Functional Recovery in Patients with Bipolar Disorder. <i>Journal of Clinical Medicine</i> , 2019, 8, 1046.	2.4	25
17	<p>Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 2325-2338.	2.2	3
18	Predictors of sexual impairment at 6 months after a manic episode: A post-hoc analysis of the MANACOR study. <i>European Neuropsychopharmacology</i> , 2019, 29, S386-S387.	0.7	0

#	ARTICLE	IF	CITATIONS
19	Behavioral addictions in bipolar disorders: A systematic review. <i>European Neuropsychopharmacology</i> , 2019, 29, 76-97.	0.7	19
20	Predominant polarity in bipolar I and II disorders: A five-year follow-up study. <i>Journal of Affective Disorders</i> , 2019, 246, 806-813.	4.1	28
21	Evaluation of Patient Satisfaction in a State Reference Center of Bipolar Disorder. <i>Journal of Behavioral Health Services and Research</i> , 2019, 46, 319-329.	1.4	2
22	Bipolar disorders. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18008.	30.5	518
23	Vortioxetine: A new alternative for the treatment of major depressive disorder. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2018, 11, 48-59.	0.3	14
24	Association between genetic variation in the myo-inositol monophosphatase 2 (IMPA2) gene and age at onset of bipolar disorder. <i>Journal of Affective Disorders</i> , 2018, 232, 229-236.	4.1	8
25	Early Intervention in Bipolar Disorder. <i>American Journal of Psychiatry</i> , 2018, 175, 411-426.	7.2	218
26	Psychometric properties of the well-being index (WHO-5) spanish version in a sample of euthymic patients with bipolar disorder. <i>Journal of Affective Disorders</i> , 2018, 228, 153-159.	4.1	34
27	Vortioxetina: una nueva alternativa en el trastorno depresivo mayor. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2018, 11, 48-59.	1.8	30
28	Toward Precision Psychiatry in Bipolar Disorder: Staging 2.0. <i>Frontiers in Psychiatry</i> , 2018, 9, 641.	2.6	79
29	Cognitive Remediation Interventions in Schizoaffective Disorder: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2018, 9, 470.	2.6	3
30	Clinical characterization of rapid cycling bipolar disorder: Association with attention deficit hyperactivity disorder. <i>Journal of Affective Disorders</i> , 2018, 240, 187-192.	4.1	14
31	Cognitive Impairment in Bipolar Disorder: Treatment and Prevention Strategies. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 670-680.	2.1	174
32	The visceral brain: Bipolar disorder and microbiota. <i>Revista De Psiquiatr�a Y Salud Mental (English)</i> Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	0.3	6
33	High Cognitive Reserve in Bipolar Disorders as a Moderator of Neurocognitive Impairment. <i>European Psychiatry</i> , 2017, 41, S116-S116.	0.2	0
34	El cerebro visceral: trastorno bipolar y microbiota. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2017, 10, 67-69.	1.8	19
35	Staging in Bipolar Disorder: Clinical, Biochemical, and Functional Correlates. <i>European Psychiatry</i> , 2017, 41, S34-S34.	0.2	0
36	Treatment of neurocognitive symptoms in unipolar depression: A systematic review and future perspectives. <i>Journal of Affective Disorders</i> , 2017, 221, 205-221.	4.1	56

#	ARTICLE	IF	CITATIONS
37	High cognitive reserve in bipolar disorders as a moderator of neurocognitive impairment. <i>Journal of Affective Disorders</i> , 2017, 208, 621-627.	4.1	51
38	Biological mechanisms of depression following treatment with interferon for chronic hepatitis C: A critical systematic review. <i>Journal of Affective Disorders</i> , 2017, 209, 235-245.	4.1	43
39	Gut Microbiota, Bacterial Translocation, and Interactions with Diet: Pathophysiological Links between Major Depressive Disorder and Non-Communicable Medical Comorbidities. <i>Psychotherapy and Psychosomatics</i> , 2017, 86, 31-46.	8.8	176
40	Bipolar disorder: defining symptoms and comorbidities – Authors' reply. <i>Lancet, The</i> , 2016, 388, 869-870.	13.7	4
41	Glucocorticoid Receptors, Brain-Derived Neurotrophic Factor, Serotonin and Dopamine Neurotransmission are Associated with Interferon-Induced Depression. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv135.	2.1	29
42	Bipolar disorder. <i>Lancet, The</i> , 2016, 387, 1561-1572.	13.7	1,100
43	Pharmacological treatment and staging in bipolar disorder: evidence from clinical practice. <i>Revista Brasileira De Psiquiatria</i> , 2015, 37, 121-125.	1.7	19
44	Estrategias para el cambio de antipsicótico en el tratamiento del trastorno bipolar. <i>Psiquiatria Biologica</i> , 2015, 22, 35-39.	0.1	1
45	Asenapine prescribing patterns in the treatment of manic in- and outpatients: Results from the MANACOR study. <i>European Psychiatry</i> , 2015, 30, 528-534.	0.2	17
46	Pharmacotherapy of Acute Mania: Monotherapy or Combination Therapy with Mood Stabilizers and Antipsychotics?. <i>CNS Drugs</i> , 2015, 29, 221-227.	5.9	33
47	Caso clínico : Cambio de tratamiento antipsicótico en un paciente con trastorno bipolar. <i>Psiquiatria Biologica</i> , 2015, 22, 40-41.	0.1	0
48	Treatment delay is associated with more episodes and more severe illness staging progression in patients with bipolar disorder. <i>Psychiatry Research</i> , 2015, 227, 372-373.	3.3	11
49	Antipsychotic switching in bipolar disorders: a systematic review. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 497-507.	2.1	25
50	Val66Met polymorphism and serum brain-derived neurotrophic factor in bipolar disorder: an open-label trial. <i>Acta Psychiatrica Scandinavica</i> , 2014, 129, 393-400.	4.5	23
51	Staging bipolar disorder: clinical, biochemical, and functional correlates. <i>Acta Psychiatrica Scandinavica</i> , 2014, 129, 437-444.	4.5	84
52	Is bipolar disorder an endocrine condition? – Glucose abnormalities in bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2014, 129, 73-74.	4.5	16
53	Staging systems in bipolar disorder: an international society for bipolar disorders – ask for report. <i>Acta Psychiatrica Scandinavica</i> , 2014, 130, 354-363.	4.5	175
54	S.05.03 Switching antipsychotics in schizoaffective disorder: rules and cautions. <i>European Neuropsychopharmacology</i> , 2014, 24, S116.	0.7	0

#	ARTICLE	IF	CITATIONS
55	Validity and reliability of a rating scale on subjective cognitive deficits in bipolar disorder (COBRA). <i>Journal of Affective Disorders</i> , 2013, 150, 29-36.	4.1	116
56	Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol. <i>Journal of Affective Disorders</i> , 2013, 144, 191-198.	4.1	28
57	Faster onset of antimanic action with haloperidol compared to second-generation antipsychotics. A meta-analysis of randomized clinical trials in acute mania. <i>European Neuropsychopharmacology</i> , 2013, 23, 305-316.	0.7	24
58	The Clinical Implications Of Cognitive Impairment and Allostatic Load in Bipolar Disorder. <i>European Psychiatry</i> , 2013, 28, 21-29.	0.2	119
59	Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia. <i>International Clinical Psychopharmacology</i> , 2013, 28, 1.	1.7	20
60	Patterns of pharmacological maintenance treatment in a community mental health services bipolar disorder cohort study (SIN-DEPRES). <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 513-523.	2.1	33
61	Occupational disability in bipolar disorder: analysis of predictors of being on severe disablement benefit (PREBIS study data). <i>Acta Psychiatrica Scandinavica</i> , 2013, 127, 403-411.	4.5	54
62	Soft Bipolar Spectrum and Staging in Bipolar Disorder. <i>Current Psychiatry Reviews</i> , 2013, 9, 33-40.	0.9	0
63	Soft Bipolar Spectrum and Staging in Bipolar Disorder. <i>Current Psychiatry Reviews</i> , 2013, 9, 33-40.	0.9	1
64	Peripheral brain-derived neurotrophic factor changes along treatment with extended release quetiapine during acute mood episodes: An open-label trial in drug-free patients with bipolar disorder. <i>Journal of Psychiatric Research</i> , 2012, 46, 1511-1514.	3.1	32
65	P.2.e.027 Interleukin-6 as a biomarker of the model of staging in bipolar disorder. <i>European Neuropsychopharmacology</i> , 2012, 22, S291-S292.	0.7	0
66	Clinical factors leading to lamotrigine prescription in bipolar outpatients: Subanalysis of the SIN-DEPRES study. <i>Journal of Affective Disorders</i> , 2012, 143, 102-108.	4.1	14
67	Mediators of allostasis and systemic toxicity in bipolar disorder. <i>Physiology and Behavior</i> , 2012, 106, 46-50.	2.1	100
68	Insulin dysfunction and allostatic load in bipolar disorder. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1017-1028.	2.8	54
69	Remission and functioning after two years undergoing Long-Acting Injectable Risperidone (LAIR) in recent-onset schizophrenia. <i>European Psychiatry</i> , 2011, 26, 1344-1344.	0.2	0
70	Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: A positive correlation. <i>Neuroscience Letters</i> , 2011, 491, 207-210.	2.1	59
71	What we know and what we don't know about the treatment of schizoaffective disorder. <i>European Neuropsychopharmacology</i> , 2011, 21, 680-690.	0.7	33
72	Atypical Creutzfeldt-Jakob Disease Evolution after Electroconvulsive Therapy for Catatonic Depression. <i>Case Reports in Psychiatry</i> , 2011, 2011, 1-3.	0.5	7

#	ARTICLE	IF	CITATIONS
73	Bipolar mixed episodes and antidepressants: a cohort study of bipolar I disorder patients. <i>Bipolar Disorders</i> , 2011, 13, 145-154.	1.9	62
74	Gender differences in a cohort study of 604 bipolar patients: The role of predominant polarity. <i>Journal of Affective Disorders</i> , 2011, 133, 443-449.	4.1	149
75	<scp>QTc</scp> prolongation: is clozapine safe? Study of 82 cases before and after clozapine treatment. <i>Human Psychopharmacology</i> , 2011, 26, 397-403.	1.5	21
76	Should bipolar disorder be considered a systemic illness?. <i>Neuropsychiatry</i> , 2011, 1, 45-54.	0.4	3
77	The Role of BDNF as a Mediator of Neuroplasticity in Bipolar Disorder. <i>Psychiatry Investigation</i> , 2010, 7, 243.	1.6	124
78	Intervención sobre el consumo de tabaco en un paciente con dependencia al alcohol ingresado para la desintoxicación. <i>Trastornos Adictivos</i> , 2009, 11, 112-117.	0.1	0